10x Genomics (TXG) Cash from Investing Activities (2018 - 2026)

10x Genomics has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$1.3 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$1.3 million, up 30.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 71.53% YoY), and the FY2025 annual result was -$13.4 million, up 58.82% from the prior year.
• Cash from Investing Activities came in at -$1.3 million for Q1 2026 at 10x Genomics, up from -$1.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $120.0 million in Q1 2023 to a low of -$257.6 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$1.9 million (2025), against an average of -$15.6 million.
• Peak annual rise in Cash from Investing Activities reached 367.75% in 2024, while the deepest fall reached 493.89% in 2024.
• 10x Genomics' Cash from Investing Activities stood at -$33.2 million in 2022, then jumped by 139.49% to $13.1 million in 2023, then sank by 493.89% to -$51.6 million in 2024, then soared by 96.5% to -$1.8 million in 2025, then grew by 27.37% to -$1.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$1.3 million (Q1 2026), -$1.8 million (Q4 2025), and -$8.8 million (Q3 2025), per Business Quant data.